3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Breast
1
Conditions
Colorectal Neoplasms
33
Ovarian Neoplasms
21
Neoplasms
14
Carcinoma, Hepatocellular
13
Fallopian Tube Neoplasms
12
Carcinoma, Non-Small-Cell Lung
10
Endometrial Neoplasms
8
Neoplasm Metastasis
7
Colonic Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
4
Glioblastoma
4
Breast Neoplasms
4
Brain Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Rectal Neoplasms
3
Lung Neoplasms
3
Liver Neoplasms
3
Gastrointestinal Neoplasms
3
Digestive System Neoplasms
3
Biliary Tract Neoplasms
3
Sarcoma
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Neuroma, Acoustic
2
Neurofibromatosis 2
2
Mouth Neoplasms
2
Meningioma
2
Lymphoid Interstitial Pneumonia
2
Interventions
pembrolizumab
2
Paclitaxel
2
Carboplatin
2
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Vaginal Smears
1
Trastuzumab
1
Sutures
1
Sunitinib
1
Specimen Handling
1
Radionuclide Imaging
1
Papanicolaou Test
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
Bevacizumab
×
30 days
×
Clear all
NCT05579366
2026-06-03
RAINFOL-01
Genmab
Phase 1/2
Recruiting
884 enrolled